PHILADELPHIA, 2014

Premier Research announces the appointment of Charlie Nicholson as Chief Financial Officer. Mr. Nicholson will direct the financial operations and support the growth strategy of the company, a leading contract research organization serving the biotechnology, pharmaceutical, and medical device industries.

Mr. Nicholson brings to Premier Research 22 years of financial leadership experience, including 15 years at other CROs. Most recently he was Vice President, Finance, and Controller at PAREXEL International. He previously served as Executive Director, Global Business Finance, at INC Research, overseeing North America and Europe. Prior to that, he was Senior Director, Finance, for International Operations at i3 Research.

Mr. Nicholson began his career in the financial services sector, becoming an ACA-qualified chartered accountant early in his career while employed at PricewaterhouseCoopers. He holds a bachelor’s degree in geology from Durham University.

“We are privileged to have Charlie join Premier Research as our Chief Financial Officer,” said Dr. Ludo Reynders, CEO. “His extensive international experience in management and financial disciplines and track record as a catalyst across a wide range of enterprises, from blue chips to start-ups, will be indispensable in facilitating our growth strategy.”

About Premier Research
Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical, and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in such areas as analgesia, CNS, rare diseases, medical device and diagnostics, and pediatric research. Premier Research operates in 50 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively.